Literature DB >> 6403788

In vivo dopamine receptor binding studies with a non-radioactively labeled agonist, dipropyl-5,6-ADTN.

M G Feenstra, H Rollema, T B Mulder, B H Westerink, A S Horn.   

Abstract

Evidence is presented that a low dose of peripherally administered N,N-dipropylamino-5,6-dihydroxytetralin (DiPr-5,6-ADTN) specifically labels dopamine (DA) receptors in rat brain. Concentrations of this potent DA receptor agonist were determined by a highly selective method using reversed phase liquid chromatography and amperometric detection. The binding characteristics satisfy all criteria regarding saturability, stereospecificity, regional distribution and relation with pharmacological effects that are associated with DA receptor interactions. A rough estimation of the density of binding sites in the striatum resulted in values of 60-70 pmol/g. Lesioning the nigrostriatal pathway does not significantly alter the amount of ligand bound, nor do pretreatments with serotonergic, alpha-adrenergic or beta-adrenergic antagonists. DiPr-5,6-ADTN has thus been shown to be a useful ligand for labeling central DA receptors and a powerful tool in the study of DA-ergic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403788     DOI: 10.1016/0024-3205(83)90805-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  In vivo receptor binding, neurochemical and functional studies with the dopamine D-1 receptor antagonist SCH23390.

Authors:  S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

Review 2.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

3.  Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.

Authors:  S Hjorth; K Svensson; A Carlsson; H Wikström; B Andersson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

4.  S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects.

Authors:  H Rollema; M G Feenstra; C J Grol; M H Lewis; L Staples; R B Mailman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

5.  Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour.

Authors:  N Waters; L Löfberg; S Haadsma-Svensson; K Svensson; C Sonesson; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1994

6.  In vivo displacement by 3-PPP enantiomers of N,N-dipropyl-5,6-ADTN from dopamine receptor-binding sites in rat striatum.

Authors:  A Carlsson; L Löfberg
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

7.  In vivo dopamine (DA) receptor binding and behavioural effects of the putative DA autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 in rats with a unilateral nigral 6-OH-DA lesion.

Authors:  M Hajos; S Hjorth; K Svensson; A Carlsson
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

8.  (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists.

Authors:  K Svensson; A M Johansson; T Magnusson; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

9.  Enzymatic O-methylation of the dopamine agonist dipropyl-5,6-dihydroxyaminotetralin: isolation and structure elucidation of the O-methylated metabolite.

Authors:  H Rollema; C J Grol
Journal:  Pharm Weekbl Sci       Date:  1983-08-26

10.  A homologous series of N-alkylated cis-(+)-(1 S, 2 R)-5-methoxy-1-methyl-2-aminotetralins: central dopamine receptor antagonists showing profiles ranging from classical antagonism to selectivity for autoreceptors.

Authors:  K Svensson; A Carlsson; A M Johansson; L E Arvidsson; J L Nilsson
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.